Epstein-Barr virus BART microRNAs in EBV- associated Hodgkin lymphoma and gastric cancer.
BamHI fragment a rightward transcript
EBV
Epstein-Barr virus; miRNA
Gastric carcinoma cancer
HL
Hodgkin lymphoma; GC
Micro RNA; BART
Journal
Infectious agents and cancer
ISSN: 1750-9378
Titre abrégé: Infect Agent Cancer
Pays: England
ID NLM: 101276559
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
05
2020
accepted:
11
06
2020
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
26
6
2020
Statut:
epublish
Résumé
EBV produces miRNAs with important functions in cancer growth, tumor invasion and host immune surveillance. The discovery of EBV miR-BARTs is recent, and most of their functions are still unknown. Nonetheless, some new studies underline their key roles in EBV-associated malignancies. In EBV-associated tumors, the expression profile of miR-BARTs varies according to the cell type, autophagic process and signals received from the tumor microenvironment. By the same way of interest is the interaction between tumor cells and the tumor environment by the release of selected EBV miR-BARTs in addition to the tumor proteins trough tumor exosomes. In this review, we discuss new findings regarding EBV miR-BARTs in Hodgkin lymphoma and gastric cancer. The recent discovery that miRNAs are released by exosomes, including miR-BARTs, highlights the importance of tumor and microenvironment interplay with more specific effects on the host immune response.
Sections du résumé
BACKGROUND
BACKGROUND
EBV produces miRNAs with important functions in cancer growth, tumor invasion and host immune surveillance. The discovery of EBV miR-BARTs is recent, and most of their functions are still unknown. Nonetheless, some new studies underline their key roles in EBV-associated malignancies.
MAIN BODY
METHODS
In EBV-associated tumors, the expression profile of miR-BARTs varies according to the cell type, autophagic process and signals received from the tumor microenvironment. By the same way of interest is the interaction between tumor cells and the tumor environment by the release of selected EBV miR-BARTs in addition to the tumor proteins trough tumor exosomes.
CONCLUSION
CONCLUSIONS
In this review, we discuss new findings regarding EBV miR-BARTs in Hodgkin lymphoma and gastric cancer. The recent discovery that miRNAs are released by exosomes, including miR-BARTs, highlights the importance of tumor and microenvironment interplay with more specific effects on the host immune response.
Identifiants
pubmed: 32582365
doi: 10.1186/s13027-020-00307-6
pii: 307
pmc: PMC7310352
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
42Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThere are no conflicts of interest in connection with this paper, and the material described is not under publication or consideration for publication elsewhere.
Références
Virology. 2011 Apr 10;412(2):392-400
pubmed: 21333317
JCI Insight. 2016 Nov 17;1(19):e89631
pubmed: 27882350
Semin Cancer Biol. 2020 Apr;61:84-100
pubmed: 31521748
Cancer Lett. 2017 Mar 1;388:334-343
pubmed: 27956246
Cells. 2020 Feb 21;9(2):
pubmed: 32098275
Int J Cancer. 2018 Dec 15;143(12):3209-3217
pubmed: 29971780
Blood. 2001 May 1;97(9):2798-807
pubmed: 11313274
Toxins (Basel). 2017 Mar 28;9(4):
pubmed: 28350359
Aging (Albany NY). 2020 Jan 6;12(1):340-358
pubmed: 31907338
Oncogene. 2015 Apr 23;34(17):2156-66
pubmed: 25347742
Arch Virol. 2017 Feb;162(2):369-377
pubmed: 27757686
Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):11036-41
pubmed: 26290577
BMC Genomics. 2016 Aug 17;17:644
pubmed: 27531524
J Virol. 2009 Aug;83(15):7749-60
pubmed: 19439479
Annu Rev Pathol. 2020 Jan 24;15:123-147
pubmed: 31530089
Nat Med. 2015 May;21(5):449-56
pubmed: 25894828
Oncotarget. 2016 Jan 26;7(4):4972-80
pubmed: 26701721
J Virol. 2000 Apr;74(7):3082-92
pubmed: 10708423
J Virol. 2018 Nov 12;92(23):
pubmed: 30209170
Front Oncol. 2019 Oct 22;9:1120
pubmed: 31696060
Science. 2004 Apr 30;304(5671):734-6
pubmed: 15118162
Cell. 2010 Mar 19;140(6):821-32
pubmed: 20303873
PLoS Pathog. 2019 Jan 7;15(1):e1007535
pubmed: 30615681
Virol J. 2013 Apr 16;10:119
pubmed: 23590857
BMC Cancer. 2015 Oct 24;15:782
pubmed: 26498209
J Virol. 2013 Jul;87(14):8135-44
pubmed: 23678170
Cancer Biomark. 2020;27(3):365-375
pubmed: 31958073
Lab Invest. 2016 Jun;96(6):661-71
pubmed: 26950485
PLoS One. 2016 Sep 29;11(9):e0163609
pubmed: 27684719
PLoS Pathog. 2011 Aug;7(8):e1002193
pubmed: 21901094
J Virol. 2015 May;89(10):5581-91
pubmed: 25740983
J Biol Chem. 2019 Mar 29;294(13):4854-4866
pubmed: 30674552
PLoS One. 2012;7(8):e42193
pubmed: 22870299
Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16164-9
pubmed: 17911266
Front Genet. 2019 Oct 17;10:939
pubmed: 31681406
Hematol Oncol. 2017 Dec;35(4):655-663
pubmed: 27709652
Rev Med Virol. 2020 Mar;30(2):e2095
pubmed: 31845495
Microorganisms. 2020 Feb 15;8(2):
pubmed: 32075248
J Immunol. 2012 Oct 15;189(8):3795-9
pubmed: 22984081
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
EMBO J. 1998 Mar 16;17(6):1700-9
pubmed: 9501091
Gastric Cancer. 2020 Mar 23;:
pubmed: 32206940
J Virol. 2015 Nov;89(22):11256-68
pubmed: 26311882
Mol Cell Biol. 2006 Jun;26(12):4474-88
pubmed: 16738314
Eur J Cancer Prev. 2017 Mar;26(2):144-150
pubmed: 26909566
Int J Mol Sci. 2018 Jun 06;19(6):
pubmed: 29882766
Neoplasia. 2009 Nov;11(11):1174-84
pubmed: 19881953
Head Neck. 2019 Mar;41(3):780-792
pubmed: 30548946
J Virol. 2016 Jun 24;90(14):6475-88
pubmed: 27147748
PLoS One. 2017 Aug 10;12(8):e0182692
pubmed: 28796808
Nucleic Acids Res. 2008 Feb;36(2):666-75
pubmed: 18073197
Cancer Sci. 2014 Sep;105(9):1170-5
pubmed: 24974976
Mol Cell Biochem. 2012 Jun;365(1-2):203-10
pubmed: 22350759
Infect Agent Cancer. 2014 Nov 17;9(1):38
pubmed: 25473414
Mol Ther. 2017 Apr 5;25(4):1027-1037
pubmed: 28254439
J Virol. 2014 Aug;88(16):9027-37
pubmed: 24899173
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6328-33
pubmed: 20304794
Nat Rev Immunol. 2019 Aug;19(8):477-489
pubmed: 31036962
J Clin Med. 2019 Oct 02;8(10):
pubmed: 31581738
PLoS One. 2015 Sep 16;10(9):e0136058
pubmed: 26375401
Nat Microbiol. 2018 Feb;3(2):172-180
pubmed: 29292384
Blood. 2005 Oct 1;106(7):2444-51
pubmed: 15941916
Blood. 2018 Jun 7;131(23):2552-2567
pubmed: 29685921
Lab Invest. 1994 Jul;71(1):73-81
pubmed: 8041121
Oncol Lett. 2019 Oct;18(4):3433-3442
pubmed: 31516561
Virology. 2008 Jan 20;370(2):430-42
pubmed: 17945327
J Cancer. 2018 Jul 30;9(16):2852-2864
pubmed: 30123354
EMBO J. 2012 May 2;31(9):2207-21
pubmed: 22473208
Int J Cancer. 2019 May 15;144(10):2555-2566
pubmed: 30411781
Cancer Med. 2017 Mar;6(3):605-618
pubmed: 28181423
J Virol. 2008 Sep;82(18):9094-106
pubmed: 18614630
PLoS Pathog. 2013;9(5):e1003341
pubmed: 23671415
Blood. 2019 Mar 28;133(13):1489-1494
pubmed: 30696620
PLoS One. 2011;6(11):e27271
pubmed: 22102884
Cancer Sci. 2018 Apr;109(4):1254-1262
pubmed: 29363227
Cell Host Microbe. 2009 Apr 23;5(4):376-85
pubmed: 19380116
Mol Cancer. 2019 Mar 15;18(1):41
pubmed: 30876419
Oncotarget. 2015 Apr 10;6(10):7838-50
pubmed: 25691053